We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Peregrine Announces Initiation of Investigator-sponsored Trial in HER2-Negative Metastatic Breast Cancer
News

Peregrine Announces Initiation of Investigator-sponsored Trial in HER2-Negative Metastatic Breast Cancer

Peregrine Announces Initiation of Investigator-sponsored Trial in HER2-Negative Metastatic Breast Cancer
News

Peregrine Announces Initiation of Investigator-sponsored Trial in HER2-Negative Metastatic Breast Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Peregrine Announces Initiation of Investigator-sponsored Trial in HER2-Negative Metastatic Breast Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Peregrine Pharmaceuticals, Inc. has announced the initiation of an investigator-sponsored trial (IST) for patients with HER2-negative metastatic breast cancer, which accounts for 75% of metastatic breast cancers. This open-label Phase I trial will treat patients with Peregrine's investigational monoclonal antibody bavituximab in combination with the chemotherapy agent paclitaxel.

"Bavituximab combined with chemotherapeutic agents has shown promising anti-tumor activity in two Phase II breast cancer clinical trials and has repeatedly demonstrated synergistic anti-tumor activity in preclinical models," said Alison Stopeck, M.D., lead investigator of this trial and director of the clinical breast cancer program at the Arizona Cancer Center at UMC North. "This safety study will also examine the role of cell-specific microparticles, potentially providing novel insights into biomarkers that may correlate with a patient's response to therapy and ultimate prognosis."

Currently, Peregrine's bavituximab is being evaluated in randomized Phase II trials in front-line non-small cell lung cancer (NSCLC), second-line NSCLC, pancreatic cancer, and HCV. Peregrine's first IST, a Phase I/II trial in hepatocellular carcinoma, was initiated last month and additional studies are being planned.

"Our two signal-seeking Phase II breast cancer trials combining bavituximab with taxane-based chemotherapy regimens showed promising tumor response and progression-free survival," said Joseph S. Shan, vice president, clinical and regulatory affairs at Peregrine Pharmaceuticals. "We are delighted to support Dr. Stopeck and her team as they elucidate the potential mechanisms behind the enhanced anti-tumor activity."

Advertisement